Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This commentary summarizes recommended dosing strategies for a recently developed 3 monthly long-acting injectable 1 (LAI) formulation of paliperidone palmitate (PP3M) for the treatment of schizophrenia in adults. METHODS: Recommendations for different dosing scenarios are based on the pharmacokinetic, efficacy and safety outcomes from phase 1 and phase 3 studies, population pharmacokinetic models, and model based simulations. RESULTS: Switching to PP3M treatment is recommended only in patients previously treated with once monthly paliperidone palmitate LAI (PP1M) for at least 4 months. The first injection of PP3M (175 to 525 mg equivalent [eq.]) should be given at the time of next scheduled injection of PP1M as a 3.5-fold multiple of the last PP1M dose (50-150 mg eq.), with a dosing window of ± 1 week. Following that first injection of PP3M, once-every-three-months maintenance injections with PP3M are recommended, with a dosing window of ± 2 weeks. The doses of PP3M can be administered in either deltoid (≥ 90 kg: 1.5 inch 22 G needle; <90 kg: 1.0 inch 22 G needle) or gluteal muscles (1.5 inch 22 G needle regardless of weight). In patients with mild renal impairment (creatinine clearance: 50-80 mL/min), a 25% dose reduction in PP1M and subsequent switching to a corresponding 3.5-dose multiple of PP3M (but not exceeding 350 mg eq.) is recommended. Appropriate dosing is recommended in elderly patients with diminished renal function not exceeding mild renal impairment. Similarly to PP1M, PP3M is not recommended in patients with moderate/severe renal impairment. Like PP1M, no dosage adjustment is required in patients with mild or moderate hepatic impairment or elderly patients with normal renal function. CONCLUSIONS: These data provide clinical guidelines for the optimum use of PP3M in patients with schizophrenia previously treated with PP1M for at least 4 months. REGISTRATION: ClinicalTrials.gov identifier: NCT01559272 and NCT01529515.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.886 · Cited by 621
Ravenstijn, P., Remmerie, B., Savitz, A., Samtani, M. N., Nuamah, I., Chang, C., De Meulder, M., Hough, D., & Gopal, S. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.597 · Cited by 86
Self-citation
Cited by
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205
Self-citationSchoretsanitis, G., Spina, E., Hiemke, C., & de Leon, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1549489 · Cited by 50
Russu, A., Kern Sliwa, J., Ravenstijn, P., Singh, A., Mathews, M., Kim, E., & Gopal, S. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13089 · Cited by 19
Self-citationRussu, A., Savitz, A., Mathews, M., Gopal, S., Feng, Y., & Samtani, M. N. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001137 · Cited by 8
Self-citation
Metadata
- Authors
- Gopal, S., Vermeulen, A., Nandy, P., Ravenstijn, P., Nuamah, I., Buron Vidal, J. A., Berwaerts, J., Savitz, A., Hough, D., & Samtani, M. N.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2015-10-02
- Volume
- 31
- Issue
- 11
- Pages
- 2043-2054
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W1953157543
- Cited by
- 31
- References
- 2
- FWCI
- 2.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. https://app.cochat.ai/papers/10.1185/03007995.2015.1085849
- The paper
- Gopal, S., Vermeulen, A., Nandy, P., Ravenstijn, P., Nuamah, I., Buron Vidal, J. A., Berwaerts, J., Savitz, A., Hough, D., & Samtani, M. N. (2015). Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. Current Medical Research and Opinion. https://doi.org/10.1185/03007995.2015.1085849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.